Palopegteriparatide
As of the edition of 20 October 2026, Palopegteriparatide is a protein: marketed, first approved in 2023 (EU); acts on PTH1R; US protection ends in 2037.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2026
- Kind
- Protein
- Brand name
- Yorvipath
- First approved
- 17 November 2023 (EU)
- Approvals on record
- 7 in 4 regions
- Holder of the most recent approval
- Adium; 4 holders in all
- Registered trials
- 8, 0 stopped early
- Disease areas
- Hormones
US protection
US protection ends in 2037.
The last listed US drug-substance patent ends in 2037. The application that gives this date is held by Ascendis Pharma A/S.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product15 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 15 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
3 companies on route B because of this drug.
Companies on route B for this drug
In the product3 companies are on route B because of Palopegteriparatide.
See the 3 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PTH1R | Parathyroid hormone/parathyroid hormone-related peptide receptor | Q03431 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 0 | 2 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 4 | 2 | 2 | 0 |
| All trials | 8 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Ascendis Pharma A/S | Applicant and Lead sponsor of trials | 2019 to now |
| Teijin Pharma | Applicant | 2025 to now |
| Adium | Applicant | 2026 to now |